Biostage (NASDAQ:BSTG) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). On average, analysts expect Biostage to post $-0.420 EPS for the current fiscal year and $-0.350 EPS for the next fiscal year.
Biostage Inc (NASDAQ:BSTG) opened at 0.083 on Wednesday. Biostage Inc has a one year low of $0.05 and a one year high of $1.42. The firm’s market capitalization is $3.23 million. The stock has a 50 day moving average of $0.21 and a 200-day moving average of $0.33.
In other news, insider Saverio Lafrancesca purchased 100,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $0.37 per share, with a total value of $37,000.00. Following the transaction, the insider now owns 293,998 shares in the company, valued at approximately $108,779.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.30% of the company’s stock.
An institutional investor recently raised its position in Biostage stock. Vanguard Group Inc. lifted its position in shares of Biostage Inc (NASDAQ:BSTG) by 4.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 773,820 shares of the biotechnology company’s stock after acquiring an additional 29,902 shares during the period. Vanguard Group Inc. owned about 2.08% of Biostage worth $319,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.12% of the company’s stock.
Separately, Maxim Group reiterated a “hold” rating on shares of Biostage in a research note on Monday, August 7th.
Biostage Company Profile
Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.
What are top analysts saying about Biostage Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biostage Inc and related companies.